Journal article
A biocompatible reverse thermoresponsive polymer for ocular drug delivery
A Balachandra, EC Chan, JP Paul, S Ng, V Chrysostomou, S Ngo, R Mayadunne, P van Wijngaarden
Drug Delivery | TAYLOR & FRANCIS LTD | Published : 2019
Abstract
Age-related macular degeneration (AMD) is a leading cause of vision loss, the treatment of which may require monthly intravitreal injections. This is a burden on patients and health services, and new delivery modalities that reduce injection frequency are required. To that end, we investigated the suitability of a novel reverse thermoresponsive polymer (RTP) as an ocular drug-delivery vehicle. In this work, we detail the structure and synthesis of a novel RTP, and determine drug release curves for two drugs commonly used in the treatment of AMD, bevacizumab and aflibercept. Biocompatibility of the RTP was assessed in vitro in human and rat cell lines and in vivo following intravitreal inject..
View full abstractGrants
Awarded by Sylvia and Charles Viertel Charitable Foundation
Funding Acknowledgements
This study was supported by the CASS Foundation (PvW was the recipient of a Science and Medicine Grant) and the Sylvia and Charles Viertel Charitable Foundation (PvW is the recipient of a Viertel Clinical Investigatorship VTL2015CO18). PvW is the recipient of a University of Melbourne Annemarie Mankiewicz-Zelkin Fellowship. CERA receives Operational Infrastructure Support from the Victorian Government and Australian Government NHMRC IRIISS. The polymer synthesis, characterization and in-vitro release studies were supported by CSIRO.